FDA approves mirabegron for overactive bladder

FDA approved an NDA from Astellas Pharma Inc. (Tokyo:4503) for Myrbetriq mirabegron to treat overactive bladder. The pharma, which has not yet determined the drug's pricing, said it will launch the dr...